BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27075367)

  • 1. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
    Eggert E; Hillig RC; Koehr S; Stöckigt D; Weiske J; Barak N; Mowat J; Brumby T; Christ CD; Ter Laak A; Lang T; Fernandez-Montalvan AE; Badock V; Weinmann H; Hartung IV; Barsyte-Lovejoy D; Szewczyk M; Kennedy S; Li F; Vedadi M; Brown PJ; Santhakumar V; Arrowsmith CH; Stellfeld T; Stresemann C
    J Med Chem; 2016 May; 59(10):4578-600. PubMed ID: 27075367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
    Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
    J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
    Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
    Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
    J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
    Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
    J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
    Reynoird N; Mazur PK; Stellfeld T; Flores NM; Lofgren SM; Carlson SM; Brambilla E; Hainaut P; Kaznowska EB; Arrowsmith CH; Khatri P; Stresemann C; Gozani O; Sage J
    Genes Dev; 2016 Apr; 30(7):772-85. PubMed ID: 26988419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
    Yi X; Jiang XJ; Fang ZM
    Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of substrate methylation and inhibition of SMYD2.
    Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
    Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
    Brown MA; Sims RJ; Gottlieb PD; Tucker PW
    Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
    Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
    Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
    Weirich S; Schuhmacher MK; Kudithipudi S; Lungu C; Ferguson AD; Jeltsch A
    Chembiochem; 2020 Jan; 21(1-2):256-264. PubMed ID: 31612581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
    Fan JD; Lei PJ; Zheng JY; Wang X; Li S; Liu H; He YL; Wang ZN; Wei G; Zhang X; Li LY; Wu M
    PLoS One; 2015; 10(1):e0116782. PubMed ID: 25562686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.
    Butler KV; Ma A; Yu W; Li F; Tempel W; Babault N; Pittella-Silva F; Shao J; Wang J; Luo M; Vedadi M; Brown PJ; Arrowsmith CH; Jin J
    J Med Chem; 2016 Nov; 59(21):9881-9889. PubMed ID: 27804297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
    Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
    Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.
    Chandramouli B; Melino G; Chillemi G
    Mol Oncol; 2019 Jun; 13(6):1450-1461. PubMed ID: 31069954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
    Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
    J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.